Tapentadol is a centrally acting synthetic analgesic with a dual mode of action. It works as a mu-opioid receptor agonist and also inhibits norepinephrine reuptake, leading to enhanced pain control. It is approximately 18 times less potent than morphine in terms of binding affinity to human mu-opioid receptors. The analgesic effect of tapentadol can be reversed by opioid antagonists such as naloxone. Tapentadol has no clinically significant effect on the QT interval.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Dosage & Administration

The dosing regimen should be individualized based on pain severity, prior analgesic use, and patient response.

• Recommended dose: 50 mg, 75 mg, or 100 mg every 4 to 6 hours, depending on pain intensity

• On the first day of therapy, a second dose may be given as early as one hour after the first dose if pain relief is insufficient

• Subsequent doses should be adjusted to maintain adequate analgesia with acceptable tolerability

Maximum Recommended Dose:

• First day: Up to 700 mg/day

• Subsequent days: Up to 600 mg/day

Doses above these limits have not been studied and are not recommended.

Drug Interactions

• Increased risk of serotonin syndrome with TCAs, SSRIs, SNRIs, triptans, and other monoaminergic drugs

• Enhanced sedative and respiratory depressant effects with benzodiazepines, barbiturates, antipsychotics, H1-antihistamines, other opioids, and alcohol

• Increased addiction potential with mixed or partial mu-opioid agonists (e.g., nalbuphine, pentazocine, buprenorphine)

• Increased systemic exposure with strong UGT1A6, UGT1A9, and UGT2B7 inhibitors

• Reduced efficacy with strong enzyme inducers such as rifampicin and phenobarbital

Contraindications

Topita SR 50 mg is contraindicated in patients with:

• Impaired pulmonary function

• Acute or severe bronchial asthma or hypercapnia in unmonitored settings

• Known or suspected paralytic ileus

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Possible adverse reactions include:

• Cardiovascular: increased or decreased heart rate, hypotension

• Neurological: sedation, dizziness, memory impairment, ataxia, seizures, syncope

• Gastrointestinal: abdominal discomfort, impaired gastric emptying

• Sensory: hypoesthesia, paresthesia, visual disturbances

• Others: edema, hypersensitivity reactions, urticaria, withdrawal symptoms

Pregnancy & Lactation

• Pregnancy Category C: Use only if the potential benefit outweighs the potential risk to the fetus

• Neonates exposed to tapentadol in utero should be monitored for respiratory depression

• Use during breastfeeding should be avoided unless clearly advised by a physician

Precautions & Warnings

• Use with caution in patients with respiratory disorders such as asthma or COPD

• Caution is required in patients with sleep apnea, myxedema, kyphoscoliosis, or CNS depression

• Concomitant use with CNS depressants may result in additive sedation and respiratory depression

Overdose Effects

Symptoms:
Vomiting, miosis, cardiovascular collapse, altered consciousness up to coma, convulsions, and respiratory depression

Management:

• Secure airway and provide assisted or controlled ventilation

• Consider activated charcoal or gastric lavage within 2 hours of ingestion

• Administer opioid antagonists such as naloxone when appropriate

Use in Special Populations

• Pediatric: Safety and efficacy in patients below 18 years have not been established

• Elderly: Initiate treatment at the lower end of the dosing range

• Renal Impairment: Safety not established in severe renal disease

• Hepatic Impairment: Use with caution in moderate impairment; not studied in severe hepatic impairment

Storage Conditions

• Store in a cool and dry place

• Protect from light and moisture

• Keep out of reach of children

Mode of Action

Topita SR 50 mg relieves pain through combined mu-opioid receptor agonism and norepinephrine reuptake inhibition, providing effective central analgesia without clinically significant QT interval effects.